超重型2型糖尿病患者肠道菌群分布及利拉鲁肽联合二甲双胍的干预效果  

Distribution of Intestinal Flora in Overweight Patients with Type 2 Diabetes Mellitus and Intervention Effect of Liraglutide Combined with Metformin

作　　者：李凤 邢英[2] 卢雪玲 LI Feng;XING Ying;LU Xueling(Dept.of Endocrinology,the Seventh Affiliated Hospital of Xinjiang Medical University,Xinjiang Urumqi 830000,China;Dept.of Comprehensive Internal Medicine,the First Affiliated Hospital of Xinjiang Medical University,Xinjiang Urumqi 830000,China;Dept.of General Practice,the Seventh Affiliated Hospital of Xinjiang Medical University,Xinjiang Urumqi 830000,China)

机构地区：[1]新疆医科大学第七附属医院内分泌科,新疆乌鲁木齐830000 [2]新疆医科大学第一附属医院干保中心综合内一科,新疆乌鲁木齐830000 [3]新疆医科大学第七附属医院全科医学科,新疆乌鲁木齐830000

出　　处：《中国医院用药评价与分析》2021年第6期650-653,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：新疆维吾尔自治区自然科学基金(No.2017D01C343)。

摘　　要：目的:探讨超重型2型糖尿病患者肠道菌群分布及利拉鲁肽联合二甲双胍的干预效果。方法:选取2019年7月至2020年7月新疆医科大学第二附属医院内分泌科收治的106例超重型2型糖尿病患者进行研究。根据随机数字表法分为观察组和对照组,每组53例,另选取55例健康体检者作为健康组。记录三组患者的肠道菌群数量。对照组患者给予二甲双胍,观察组患者在对照组的基础上加用利拉鲁肽,治疗3个月,观察两组患者的临床疗效、血糖情况、体重指数(BMI)、腹部内脏脂肪厚度(VAT)及不良反应。结果:与健康组比较,观察组和对照组患者肠杆菌科细菌、酵母菌数量明显更高,双歧杆菌、拟杆菌数量明显更低,差异均有统计学意义(P <0.05);而乳酸杆菌、肠球菌数量的差异均无统计学意义(P> 0.05)。观察组患者治疗总有效率为92.45%(49/53),明显高于对照组的69.81%(37/53),差异有统计学意义(P <0.05)。观察组患者治疗后空腹血糖、餐后2 h血糖以及糖化血红蛋白水平明显低于对照组,BMI和VAT明显低于对照组,差异均有统计学意义(P <0.05)。观察组、对照组患者不良反应发生率分别为13.21%(7/53)、11.32%(6/53),差异无统计学意义(P> 0.05)。结论:超重型2型糖尿病患者肠道内存在菌群失衡,肠杆菌科细菌和酵母菌数量增多,双歧杆菌和拟杆菌数量减少,利拉鲁肽联合二甲双胍治疗该病疗效显著,有利于改善血糖水平,且未增加不良反应。OBJECTIVE: To probe into the distribution of intestinal flora in overweight patients with type 2 diabetes mellitus and the intervention effect of liraglutide combined with metformin. METHODS: Totally 106 overweight patients with type 2 diabetes mellitus admitted into endocrinology department of the Second Affiliated Hospital of Xinjiang Medical University from Jul. 2019 to Jul. 2020 were extracted to be divided into the observation group and the control group via the random number table,with 53 cases in each group. Another 55 healthy physical examiners were selected as the healthy group. The number of intestinal flora of three groups was recorded. The control group was given metformin,while the observation group received liraglutide on the basis of control group. After treatment of 3 months,clinical efficacy,blood glucose,body mass index( BMI),visceral adipose tissue( VAT) and adverse drug reactions in two groups were observed. RESULTS: Compared with the healthy group,the number of enterobacteriaceae bacteria and yeasts in the observation group and the control group was significantly higher,while the number of bifidobacterium and bacteroides were significantly lower,the differences were statistically significant( P <0. 05). However,there was no significant difference in the number of lactobacillus and enterococcus( P > 0. 05). The total effective rate of the observation group was 92. 45%( 49/53),significantly higher than that of the control group69. 81%( 37/53),with statistically significant difference( P < 0. 05). After treatment,the levels of fasting blood glucose,2 h postprandial blood glucose and Hb A1 c in the observation group were significantly lower than those in the control group,while BMI and VAT were significantly lower than those in the control group,the differences were statistically significant( P < 0. 05). The incidence of adverse drug reactions in the observation and control groups was13. 21%( 7/53) and 11. 32%( 6/53),respectively,with no statistically significant difference( P > 0. 05).CONCLUSION

关 键 词：超重型2型糖尿病 肠道菌群 利拉鲁肽 二甲双胍 

分 类 号：R977.1[医药卫生—药品]